FDA grants accelerated approval to INOVIO's VOCERYQ, a nonsurgical DNA therapy for adults with RRP, launching in early 2027.

INOVIO received accelerated FDA approval for VOCERYQ, a DNA-based immunotherapy that reduces surgery frequency in adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV-6 and HPV-11. VOCERYQ, the first FDA-approved DNA medicine from INOVIO, targets the root cause of RRP and is expected to be commercially available by early 2027. The approval is based on clinical data showing VOCERYQ significantly reduces the need for surgical interventions, improving patient quality of life. A confirmatory study is planned to verify long-term benefits, with INOVIO preparing for market launch and field deployment soon.

Following INOVIO's announcement of FDA accelerated approval for VOCERYQ, the company's stock surged significantly, reflecting heightened investor interest. On Pluang, INO trades at USD 2.15 as of Oct 31, 2026 05:11 WIB, marking a remarkable 178.57% increase in one day. The market cap stands at $79.80 million, with buyers dominating 94% of order activity, indicating strong demand for the stock.